CEO: AstraZeneca Has ‘Winning’ Vaccine Formula
The coronavirus vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a “winning formula” for efficacy, the company’s chief executive said in an interview.
The vaccine, currently being evaluated by Britain’s independent medicines regulator, provides “100 percent protection” against severe COVID-19 disease requiring hospitalization, Pascal Soriot said in an interview with the Sunday Times newspaper.
He added that he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5%.
“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot said.
To Read The Full Story
Are you already a subscriber?
Click "Sign In" to log in!
Become a Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Become a Print + Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Renew Print + Web Subscription
Click “Renew Subscription” below to begin the process of renewing your subscription.
